Benzene Ring Bonded Directly To The Ring Nitrogen Of The Five-membered Hetero Patents (Class 548/476)
  • Patent number: 10544328
    Abstract: The present invention provides a photoimageable composition comprising a polyamideimide resin, an aprotic solvent, and one or more nitrogen containing ethylenically unsaturated monomers. By addition of the nitrogen containing ethylenically unsaturated monomer, UV curable acrylates can be added to the composition, and the composition is stable. The compositions of the present invention can produce high resolution images that are flexible, hard, and have excellent resistance.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: January 28, 2020
    Assignee: Sun Chemical Corporation
    Inventors: Simon Richard Ford, Stephen Anthony Hall
  • Patent number: 9695281
    Abstract: Disclosed is a triazine ring-containing hyperbranched polymer containing a repeating unit structure represented by the expression (1). By this means, it is possible to achieve a triazine ring-containing polymer which, alone, has high heat resistance, high transparency, high refractive index, high light resistance, high solubility, low volume shrinkage without adding metal oxides; and also a membrane-forming composition containing the same. In the formula, R and R? represent independently a hydrogen atom, an alkyl group, an alkoxy group, an aryl group, or an aralkyl group, and A represents an alkylene group optionally having a branched or alicyclic structure of 1 to 20 carbon atoms.
    Type: Grant
    Filed: August 23, 2011
    Date of Patent: July 4, 2017
    Assignee: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Naoya Nishimura, Masaaki Ozawa, Yasuyuki Koide
  • Patent number: 9260375
    Abstract: A new metallo-?-lactamase inhibitor which acts as a medicament for inhibiting the inactivation of ?-lactam antibiotics and recovering anti-bacterial activities is disclosed. The maleic acid derivatives having the general formula (I) have metallo-?-lactamase inhibiting activities. It is possible to recover the anti-bacterial activities of ?-lactam antibiotics against metallo-?-lactamase producing bacteria by combining the compound of the general formula (I) with ?-lactam antibiotics.
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: February 16, 2016
    Assignee: Meiji Seika Kaisha, Ltd.
    Inventors: Ken Chikauchi, Mizuyo Ida, Takao Abe, Yukiko Hiraiwa, Akihiro Morinaka, Toshiaki Kudo
  • Patent number: 8969590
    Abstract: Classes of compounds that exhibit effective inhibition of autotaxin enzymes are provided. Such classes include thioureas, diphenyldiazerenes, xanthenes, and isoindoles and exhibit reactivity with autotaxin to ultimately reduce the size of the reactive sites thereon to prevent conversion of lysophosphatidyl choline to lysophophatidic acid. Furthermore, such compounds can be incorporated within delivery forms for human ingestion. As such, these compounds accord an excellent manner of potentially reducing generation of certain cancers attributable to the presence of naturally occurring autotaxin within the human body. Methods of inactivating autotaxin to certain degrees therewith such compounds are encompassed within invention as well.
    Type: Grant
    Filed: September 18, 2012
    Date of Patent: March 3, 2015
    Inventors: Abby Louise Parrill-Baker, Daniel Lee Baker
  • Patent number: 8883888
    Abstract: There are provided a novel diarylamine compound represented by the following formula (I), (II) or (III), which has at least one signal attributable to the hydrogen of the N—H moiety at 8.30 ppm to 9.00 ppm when a deuterated dimethyl sulfoxide solution of the diarylamine compound is analyzed by 1H-NMR; and an aging inhibitor, a polymer composition, a crosslinked rubber product and a molded article thereof, and a method of producing a diarylamine compound. In the formulas, A1 to A6 each represent an aromatic group which may have a substituent; A represents an aromatic group or a cyclic aliphatic group, which may both have a substituent; L represents 1 or 2; and n represents 0 or 1.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: November 11, 2014
    Assignee: Zeon Corporation
    Inventors: Kei Sakamoto, Tomonori Ogawa, Satoshi Kiriki, Masanobu Shinohara, Yasushi Nakano
  • Publication number: 20140303328
    Abstract: Disclosed are novel cross-linkable end-cappers for oligo- and polyamides. End-capped oligo- and polyamides comprising such an end-capper may be cured at a lower temperature compared to oligo- and polyamides end-capped with PEPA.
    Type: Application
    Filed: June 12, 2014
    Publication date: October 9, 2014
    Applicant: NEXAM CHEMICAL AB
    Inventors: Daniel ROME, David PERSSON, Erik LAGER, Dane MOMCILOVIC, Malin KNUTSSON, Jan-Erik ROSENBERG
  • Patent number: 8686154
    Abstract: Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.
    Type: Grant
    Filed: June 10, 2009
    Date of Patent: April 1, 2014
    Assignee: Emisphere Technologies, Inc.
    Inventors: Donald J. Sarubbi, Eugene N. Barantsevitch
  • Publication number: 20130225769
    Abstract: Disclosed are novel cross-linkable end-cappers for oligo- and polyamides. End-capped oligo- and polyamides comprising such an end-capper may be cured at a lower temperature compared to oligo- and polyamides end-capped with PEPA.
    Type: Application
    Filed: October 21, 2011
    Publication date: August 29, 2013
    Applicant: NEXAM CHEMICAL AB
    Inventors: Daniel Rome, David Persson, Erik Lager, Dane Momcilovic, Malin Knutsson, Jan-Erik Rosenberg
  • Publication number: 20130018159
    Abstract: This invention relates to polymerizable ultraviolet light absorbers and yellow colorants and their use in ophthalmic lenses. In particular, this invention relates to polymerizable ultraviolet light absorbing methane compounds and yellow compounds of the methine and anthraquinone classes that block ultraviolet light and/or violet-blue light transmission through ophthalmic lenses.
    Type: Application
    Filed: September 18, 2012
    Publication date: January 17, 2013
    Applicant: Abbott Medical Optics Inc.
    Inventors: Jason Clay Pearson, Max Allen Weaver, Jean Carroll Fleischer, Gregory Allan King
  • Patent number: 8338474
    Abstract: Preparation and use of phthalimide and/or sulphonamide derivatives with nitric oxide donor properties, having activities in increasing gamma-globin gene expression and anti-inflammatory and analgesic activities, effective in the treatment of hematologic diseases which require reducing the TNF-? levels and an exogenous source of nitric oxide, such as sickle-cell disease. The functionalized phthalimide derivatives are designed from the prototypes thalidomide and hydroxyurea.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: December 25, 2012
    Inventors: Jean Leandro Dos Santos, Chin Chung Man, Lídia Moreira Lima, Fernando Ferreira Costa, Carolina Lanaro
  • Patent number: 8338696
    Abstract: A benzoindole-based compound represented by Formula 1 below, a dye including the benzoindole-based compound, and a dye-sensitized solar cell including the dye: is prepared at a low cost, has a high molar absorption coefficient, and high photoelectron conversion efficiency, as compared to a conventional ruthenium dye. The benzoindole-based dye is an organic dye including an N-aryl electron donor and an acidic functional group an electron acceptor.
    Type: Grant
    Filed: December 28, 2010
    Date of Patent: December 25, 2012
    Assignee: Samsung SDI Co., Ltd.
    Inventors: Byong-cheol Shin, Ji-won Lee, Moon-sung Kang, Jaejung Ko, Duckhyun Kim
  • Publication number: 20120245364
    Abstract: Preparation and use of phthalimide and/or sulphonamide derivatives with nitric oxide donor properties, having activities in increasing gamma-globin gene expression and anti-inflammatory and analgesic activities, effective in the treatment of hematologic diseases which require reducing the TNF-? levels and an exogenous source of nitric oxide, such as sickle-cell disease. The functionalized phthalimide derivatives are designed from the prototypes thalidomide and hydroxyurea.
    Type: Application
    Filed: February 24, 2012
    Publication date: September 27, 2012
    Applicants: UNIVERSIDADE ESTADUAL DE CAMPINAS - UNICAMP, UNIVERSIDADE ESTADUAL PAULISTA " JULIO DE MESQUITA FILHO " -UNESP, UNIVERSIDADE FEDERAL DO RIO DE JANEIRO - UFRJ
    Inventors: Jean Leandro DOS SANTOS, Chin CHUNG MAN, Lídia MOREIRA LIMA, Fernando FERREIRA COSTA, Carolina LANARO
  • Patent number: 8232299
    Abstract: The present invention relates to compounds that are suitable for treatment of disease states and influence cellular vesicular systems, especially the formation and/or function of lipid droplets, said compound having the general formula I (I) wherein X are each independently hydrogen, halogen, —C1-20-alkyl, —C2-20-alkenyl, —C2-20-alkinyl, —C5-6-cykloalkyl, aryl, aralkyl, adamantyl, heterocyclic, hydroxyl, hydroxyalkyl, Or —N—(R1, R2) group; n is 0, 1, 2, 3, or 4; R1 and R2 may each be independently hydrogen, straight or branching alkyl, cyclo-alkyl, aryl, aralkyl, heterocyclic group, wherein each is un-substituted or halogen substituted; or R1 and R2 together with the nitrogen in between them form a 5 or 6 member ring; A is a single bond, —O—, —S—, —CH2-, or —NH—; Y is O or S; Z is O or S; R? and R? are each independently methyl, ethyl, isopropyl, isobuthyl, sec-butyl or terc-butyl; with the restriction that: X(n) cannot all be fluorine, and A be a single bond, and Y, as well as Z be O, and R?, as well as R? b
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: July 31, 2012
    Assignee: Avidin Kft.
    Inventors: Laszlo Puskas, Liliana Feher, Eszter Molnar
  • Publication number: 20120165546
    Abstract: The present disclosure provides a process for the mono-reduction of one or more imide moieties in a compound comprising contacting the compound with hydrogen gas and a catalyst comprising a transition metal hydride in the presence of a base, under conditions for the mono-reduction of the one or more imide moieties to form a compound comprising one or more hydroxy amides.
    Type: Application
    Filed: June 17, 2010
    Publication date: June 28, 2012
    Inventors: Steven H. Bergens, Satoshi Takebayashi
  • Publication number: 20120101196
    Abstract: There are provided a novel diarylamine compound represented by the following formula (I), (II) or (III), which has at least one signal attributable to the hydrogen of the N—H moiety at 8.30 ppm to 9.00 ppm when a deuterated dimethyl sulfoxide solution of the diarylamine compound is analyzed by 1H-NMR; and an aging inhibitor, a polymer composition, a crosslinked rubber product and a molded article thereof, and a method of producing a diarylamine compound. In the formulas, A1 to A6 each represent an aromatic group which may have a substituent; A represents an aromatic group or a cyclic aliphatic group, which may both have a substituent; L represents 1 or 2; and n represents 0 or 1.
    Type: Application
    Filed: June 30, 2010
    Publication date: April 26, 2012
    Inventors: Kei Sakamoto, Tomonori Ogawa, Satoshi Kiriki, Masanobu Shinohara, Yasushi Nakano
  • Patent number: 8044216
    Abstract: A production method of a compound containing a primary, secondary, or tertiary aminomethyl aromatic ring of the present invention includes: using a fluoroboron compound or a dimer thereof, or solvates thereof, which are represented by a formula (I): Ra(Rb)N—CH2—BF3M??(I) as an aminomethylating agent for an aromatic ring; and reacting the aminomethylating agent with an aromatic ring-containing compound, which can react with the aminomethylating agent, under the presence of a metal catalyst such as a palladium compound so as to perform the direct aminomethylation of the aromatic ring.
    Type: Grant
    Filed: July 10, 2007
    Date of Patent: October 25, 2011
    Assignee: Eisai R&D Management Co., Ltd.
    Inventor: Keigo Tanaka
  • Patent number: 7932416
    Abstract: Pentafluorosulfanyl-benzenes according to Formula (I): a process for their preparation and their use as valuable synthetic intermediates for preparing, for example, medicaments, diagnostic aids, liquid crystals, polymers, pesticides, herbicides, fungicides, nematicides, parasiticides, insecticides, acaricides and arthropodicides.
    Type: Grant
    Filed: December 13, 2007
    Date of Patent: April 26, 2011
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Heinz-Werner Kleemann, Remo Weck
  • Publication number: 20110039802
    Abstract: The present invention provides a pharmaceutical composition for use as an NPY Y5 receptor antagonist comprising a compound of the formula (I): wherein R1 is lower alkyl, cycloalkyl or the like, R2 is hydrogen, lower alkyl or the like, n is 1 or 2, X is lower alkylone, lower alkenylene, arylene, cycloalkylene or the like, Y is CONR7, CSNR7, NR7CO, NR7CS or the like, Z is lower alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl or the like and R7 is hydrogen or lower alkyl, prodrug, pharmaceutically acceptable salt or solvate thereof
    Type: Application
    Filed: July 2, 2010
    Publication date: February 17, 2011
    Inventors: Yasuyuki KAWANISHI, Hideyuki TAKENAKA, Kohji HANASAKI, Tetsuo OKADA
  • Patent number: 7884218
    Abstract: A benzoindole-based compound represented by Formula 1 below, a dye including the benzoindole-based compound, and a dye-sensitized solar cell including the dye: is prepared at a low cost, has a high molar absorption coefficient, and high photoelectron conversion efficiency, as compared to a conventional ruthenium dye. The benzoindole-based dye is an organic dye including an N-aryl electron donor and an acidic functional group an electron acceptor.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: February 8, 2011
    Assignee: Samsung SDI Co., Ltd.
    Inventors: Byong-cheol Shin, Ji-won Lee, Moon-sung Kang, Jaejung Ko, Duckhyun Kim
  • Publication number: 20100324107
    Abstract: The present invention refers to the use of phthalimide and/or sulphonamide derivatives with nitric oxide donor properties, which have important activities in increasing the gamma-globin gene expression and anti-inflammatory and analgesic activities, effective in the treatment of hematologic diseases which require reducing the TNF-? levels and an exogenous source of nitric oxide. More particularly, the present invention describes the use of such phthalimide and/or sulphonamide derivatives for the treatment of sickle-cell disease. The invention also has as a novel characteristic the disclosure of new functionalized phthalimide derivatives designed from the prototypes thalidomide and hydroxyurea, and designed rationally through the strategy of molecular hybridization for the treatment of said diseases.
    Type: Application
    Filed: December 12, 2008
    Publication date: December 23, 2010
    Applicants: UNIVERSIDADE ESTADUAL DE CAMPINAS - UNICAMP, UNIVERSIDADE FEDERAL DO RIO DE JANEIRO - UFRJ
    Inventors: Jean Leandro Dos Santos, Chin Chung Man, Lidia Moreira Lima, Fernando Ferreira Costa, Carolina Lanaro
  • Publication number: 20100273853
    Abstract: A compound of formula (1) or a pharmaceutically acceptable derivative thereof, where R1, R2, R3, R4, R5, X and Y are as defined in the specification; corresponding processes for preparing; pharmaceutical compositions comprising; and medicinal uses of such compounds.
    Type: Application
    Filed: August 16, 2007
    Publication date: October 28, 2010
    Inventors: Gerard Martin Paul Giblin, Mark Patrick Healy, David George Livermore, Helen Susanne Price, Martin Edward Swarbrick
  • Publication number: 20100247659
    Abstract: Novel methods are provided to prevent blindness associated with diabetic macular edema by administration of a phenylphthalimide analog. Additionally, sustainability of the effect of administration of the phenylphthalimide analog is improved via encapsulation with poly(lactic-co-glycolic acid) nanoparticles. Finally, a novel method for synthesizing (2,6-diisopropylphenyl)-5-amino-1H-isoindole-1,3-dione is disclosed.
    Type: Application
    Filed: July 24, 2009
    Publication date: September 30, 2010
    Applicant: Charlesson, LLC
    Inventors: Dumitru Ionescu, CherylAnn Love, Danyang Chen, Ronald Andrew Wassel
  • Publication number: 20100240908
    Abstract: The invention provides an acetylene compound represented by the following Formula (1), which is useful as a raw material for a polymer achieving high thermal resistance; wherein, in Formula (1), the encircled Ar represents an aryl group or a heteroaryl group; X represents a divalent linking group; R, R? and R1 each independently represent a hydrogen atom, a hydrocarbon group or a heterocyclic group; R2 represents a hydrogen atom or a substituent substitutable on a benzene ring; A represents a hydrocarbon group or a heterocyclic group; Q represents a hydrogen atom, a hydrocarbon group, or a metal element capable of forming a monovalent metal salt; a represents an integer from 0 or more; b, m and n each independently represent an integer of 1 or more; when n, m and b are 1 at the same time, X is not —(C?O)O—; and when n is 2, and both m and b are 1, X is not —O—.
    Type: Application
    Filed: September 25, 2008
    Publication date: September 23, 2010
    Applicant: FUJIFILM CORPORATION
    Inventors: Akira Imakuni, Masaya Nakayama, Morio Yagihara
  • Publication number: 20100184762
    Abstract: The present invention relates to compounds that are suitable for treatment of disease states and influence cellular vesicular systems, especially the formation and/or function of lipid droplets, said compound having the general formula I (I) wherein X are each independently hydrogen, halogen, —C1-20-alkyl, —C2-20-alkenyl, —C2-20-alkinyl, —C5-6-cykloalkyl, aryl, aralkyl, adamantyl, heterocyclic, hydroxyl, hydroxyalkyl, Or —N—(R1, R2) group; n is 0, 1, 2, 3, or 4; R1 and R2 may each be independently hydrogen, straight or branching alkyl, cyclo-alkyl, aryl, aralkyl, heterocyclic group, wherein each is un-substituted or halogen substituted; or R1 and R2 together with the nitrogen in between them form a 5 or 6 member ring; A is a single bond, —O—, —S—, —CH2-, or —NH—; Y is O or S; Z is O or S; R? and R? are each independently methyl, ethyl, isopropyl, isobuthyl, sec-butyl or terc-butyl; with the restriction that: X(n) cannot all be fluorine, and A be a single bond, and Y, as well as Z be O, and R?, as well as R? b
    Type: Application
    Filed: June 20, 2008
    Publication date: July 22, 2010
    Applicant: AVIDIN KFT
    Inventors: Laszlo Puskas, Liliana Feher, Eszter Molnar
  • Publication number: 20100059261
    Abstract: A material for use in flexible printed wiring board having high reliability and allowing for processing fine wiring includes a compound represented by the following general formula (I): wherein one of X and Y represents O and the other represents NAr2R2, and R1, R2, Ar1, and Ar2 are as defined in the specification, and a resin composition comprising the compound as a reactive monomer.
    Type: Application
    Filed: June 20, 2006
    Publication date: March 11, 2010
    Applicants: AMT LABORATORY CO., LTD., MANAC INC.
    Inventors: Hisashi Watanabe, Kenji Nakajima, Keizo Tanaka, Satoru Nanba
  • Publication number: 20090324540
    Abstract: Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.
    Type: Application
    Filed: June 10, 2009
    Publication date: December 31, 2009
    Applicant: Emisphere Technologies, Inc.
    Inventors: Donald J. Sarubbi, Eugene N. Barantsevitch
  • Publication number: 20090292127
    Abstract: The present invention provides a process for producing (Z)-1-phenyl-1-(N,N-diethylaminocarbonyl)-2-phthalimidomethylcyclopropane, which includes reacting (Z)-1-phenyl-1-(N,N-diethylaminocarbonyl)-2-hydroxymethylcyclopropane with an orthoester and a brønsted acid, and reacting the reaction product with a phthalimidating agent; and a process for producing (Z)-1-phenyl-1-(N,N-diethylaminocarbonyl)-2-aminomethylcyclopropane hydrochloride through the above process.
    Type: Application
    Filed: January 26, 2007
    Publication date: November 26, 2009
    Inventors: Yoshihide Niimoto, Hiroharu Kumazawa, Koh Kawami
  • Patent number: 7541489
    Abstract: A method of preparing a halophthalic acid is disclosed which comprises the steps of contacting in a liquid phase reaction mixture at least one halogen-substituted ortho-xylene with oxygen and acetic acid at a temperature in a range between about 120° C. and about 220° C. in the presence of a catalyst system yielding a product mixture comprising less than 10 percent halogen-substituted ortho-xylene starting material, a halophthalic acid product, and less than about 10,000 ppm halobenzoic acid and less than about 1000 ppm halophthalide by-products based on a total amount of halophthalic acid present in the product mixture. In addition methods for the preparation of halophthalic anhydride, and recovery of high purity acetic acid from an aqueous acetic acid stream comprising HCl, which is generated during the preparation of the halophthalic acid are also disclosed.
    Type: Grant
    Filed: June 29, 2005
    Date of Patent: June 2, 2009
    Assignee: SABIC Innovative Plastics IP B.V.
    Inventors: Robert Edgar Colborn, David Bruce Hall, Peter Alois Koch, Bernd Volker Demuth, Thomas Wessel, KarlErnst Mack, Prashant Anil Tatake, Utpal Mahendra Vakil, Shyamal Bhaskar Gondkar, John Edward Pace, Kwang Woong Won
  • Publication number: 20090048236
    Abstract: Specific phenylalanine derivatives or pharmaceutically acceptable salts thereof have an antagonistic effect on the ?4 integrins and, therefore, are usable as therapeutic agents or preventive agents for diseases in which ?4 integrin-depending adhesion process participates in the pathology, such as inflammatory diseases, rheumatoid arthritis, inflammatory bowel diseases, systemic lupus erythematosus, multiple sclerosis, Sjögren's syndrome, asthma, psoriasis, allergy, diabetes, cardiovascular diseases, arterial sclerosis, restenosis, tumor proliferation, tumor metastasis and transplantation rejection.
    Type: Application
    Filed: October 16, 2008
    Publication date: February 19, 2009
    Applicant: AJINOMOTO CO. INC
    Inventors: Nobuyasu SUZUKI, Toshihiko Yoshimura, Hiroyuki Izawa, Kazuyuki Sagi, Shingo Makino, Eiji Nakanishi, Masahiro Murata, Takashi Tsuji
  • Patent number: 7491788
    Abstract: Melt blended compositions, comprising up to 20 wt % of an optional additive, and 80-100 wt % of a copolycarbonate having a Tg of 200° C. or more of (1) wherein the mole ratio of x:y is 35:65 to 90:10, R1 is derived from a dihydroxy compound (2) wherein R3 and R5 are each independently a halogen or a C1-6 alkyl group, R4 is a C1-6 alkyl, phenyl, or phenyl substituted with up to five halogens or C1-6 alkyl groups, and each c is independently 0 to 4; R2 is derived from a dihydroxy compound (6): wherein Ra and Rb are each independently a halogen atom or a monovalent C1-6 alkyl group; p and q are each independently integers of 0 to 4; and Xa is a divalent group; and 95 to 5 wt % of a polycarbonate having a Tg of less than 200° C. of formula (9) wherein R9 derived from a dihydroxy compound of formula (6); and 0.001 to 0.1 wt % of a transesterification catalyst.
    Type: Grant
    Filed: June 29, 2006
    Date of Patent: February 17, 2009
    Assignee: SABIC Innovative Plastics IP B.V.
    Inventors: Chiel Albertus Leenders, Brian Mullen, Adam S Zerda
  • Publication number: 20080306134
    Abstract: Thalidomide analog compounds having a general structure are described. R1 is selected from a group comprising of hydroxy, hydrogen, and amino. Also described is a method for treating vascular abnormalities, such as neovascularization and vascular leakage. A therapeutically effective amount of a composition containing the thalidomide analog compound is administered to a patient. The composition may further include agents, such as solubilizing agents, inert fillers, diluents, excipients, or flavoring agents.
    Type: Application
    Filed: June 8, 2007
    Publication date: December 11, 2008
    Inventor: Danyang Chen
  • Patent number: 7459585
    Abstract: The present invention provides an AP-1 activation inhibitor, NF-kappa B activation inhibitor, inflammatory cytokine production inhibitor, matrix metalloprotease production inhibitor, inflammatory cell adhesion molecule expression inhibitor, anti-inflammatory agent, antirheumatic agent, immunosuppressant, cancer metastasis inhibitor, remedy for arteriosclerosis and antiviral agent which contain the benzene derivative of the following general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Grant
    Filed: March 24, 2005
    Date of Patent: December 2, 2008
    Assignee: Ajinomoto Co., Inc.
    Inventors: Yukio Iino, Kohichi Fujita, Takashi Tsuji, Ariko Kodaira, Kenji Takehana, Tsuyoshi Kobayashi, Takashi Yamamoto
  • Patent number: 7456183
    Abstract: Compounds having the general structure I are provided. X and Y are independently selected from the group consisting of CH2, N, NR9, C?O, C?S, S?O, SO2, S, O, (CR6R7)n, C(?O)—(CR6R7)n, and C(?S)—(CR6R7)n, where n is 1, 2, or 3. W is selected from the group consisting of (formula I) and L is selected from the group consisting of N, O, S?O, SO2, C(O), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond. Z1, Z2, and Z3 are independently selected from the group consisting of substituted carbon and nitrogen. Compounds of formula I are agonists of the melanocortin-4 receptor (“MC-4r2) and therefore may have useful properties for controlling diseases related to MC-4r action in humans, such as obesity and type II diabetes.
    Type: Grant
    Filed: April 8, 2002
    Date of Patent: November 25, 2008
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Daniel Chu, Rustum Boyce, David Duhl, Bryan Chang
  • Publication number: 20080262139
    Abstract: Disclosed is a flame retardant crosslink agent free of halogen and phosphorous. The crosslink agent can be applied in epoxy resin composition, such that the composition achieves V0 under UL-94 standard after curing. The crosslink agent, a novolac structure modified by nitrogen-containing and/or silicon containing compound, may collocate with inorganic powder, such that the thermal cured epoxy resin composition contains thermal retardancy, low expansion, low water uptake, and high glass transfer temperature properties. The epoxy resin composition including the crosslink agent of the invention can be applied in a prepreg used in copper clad laminates or printed circuit plates.
    Type: Application
    Filed: September 12, 2007
    Publication date: October 23, 2008
    Inventors: Hsin-Ho Wu, Weita Yang, Ching Cheng Hsueh
  • Patent number: 7425603
    Abstract: A polymer comprising structural units derived from a polycyclic dihydroxy compound of Formula (I) wherein R1, R2 and R3 are independently at each occurrence selected from the group consisting of a cyano functionality, a halogen, an aliphatic functionality having 1 to 10 carbons, a cycloaliphatic functionality having 3 to 10 carbons, and an aromatic functionality having 6 to 10 carbons; wherein each occurrence of “n”, “m”, and “p” independently has a value of 0, 1, 2, 3, or 4; and wherein the polymer is substantially linear.
    Type: Grant
    Filed: November 29, 2005
    Date of Patent: September 16, 2008
    Assignee: General Electric Company
    Inventors: T. Tilak Raj, Radhakrishna Arakali Srinivasarao, Jan-Pleun Lens, Subrahmanya Bhat K., Umesh Hasyagar, Subash Scindia
  • Patent number: 7329720
    Abstract: A method for increasing a mean particle size of a 2-hydrocarbyl-3,3-bis(hydroxyaryl)phthalimidine is provided. The method comprises forming a mixture comprising a feedstream of the 2-hydrocarbyl-3,3-bis(4-hydroxyaryl)phthalimidine, and a solvent composition comprising an organic solvent and water, wherein the organic solvent is capable of at least partially dissolving the 2-hydrocarbyl-3,3-bis(hydroxyaryl)phthalimidine and forming an adduct with the 2-hydrocarbyl-3,3-bis(hydroxyaryl)phthalimidine. Then the mixture is heated at a temperature and for a time effective to decompose the adduct and form a 2-hydrocarbyl-3,3-bis(hydroxyaryl)phthalimidine product having a mean particle size greater than 5 microns. The 2-hydrocarbyl-3,3-bis(hydroxyaryl)phthalimidines with increased particle size are useful for producing polymers.
    Type: Grant
    Filed: November 29, 2005
    Date of Patent: February 12, 2008
    Assignee: General Electric Company
    Inventors: Balakrishnan Ganesan, Pradeep Jeevaji Nadkarni
  • Patent number: 7317124
    Abstract: Pentafluorosulfanyl-benzenes according to Formula (I): a process for their preparation and their use as valuable synthetic intermediates for preparing, for example, medicaments, diagnostic aids, liquid crystals, polymers, pesticides, herbicides, fungicides, nematicides, parasiticides, insecticides, acaricides and arthropodicides.
    Type: Grant
    Filed: November 15, 2004
    Date of Patent: January 8, 2008
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Heinz-Werner Kleemann, Remo Weck
  • Patent number: 6878170
    Abstract: The invention concerns the use of indoline derivatives of formula (I): in which R1, R2, R3, R4 and R5 independently of one another represent hydrogen or C1-4 alkyl groups, or R4 and R5 together with the oxygen atoms to which they are attached represent a C1-4 alkylenedioxy group, or of salts of such indoline derivatives, as additives to hair dyeing agents of the direct dyeing or primary intermediate/secondary intermediate type, thus producing hair dyeing with excellent color fastness characteristics.
    Type: Grant
    Filed: April 15, 2003
    Date of Patent: April 12, 2005
    Assignee: Henkel Kommanditgesellschaft auf Aktien
    Inventors: Iduna Matzik, Detlef Hollenberg, Mechthild Borgerding
  • Patent number: 6844359
    Abstract: Novel imides are inhibitors of tumor necrosis factor alpha and can be used to combat cachexia, endotoxic shock, and retrovirus replication. A typical embodiment is (R)-2-Phthalimido-3-(3?,4?-dimethoxyphenyl)propane.
    Type: Grant
    Filed: March 25, 2002
    Date of Patent: January 18, 2005
    Assignee: Celgene Corporation
    Inventors: George W. Muller, Mary Shire, David I. Stirling
  • Patent number: 6730808
    Abstract: Reactor membranes for used in oxidation reactions of hydrocarbons involving oxygen comprising a selective oxidation catalyst on a mixed conducting, oxide ion selective ceramic membrane of the composition (Sr1-xCax)1-yAyMn1-zBzO3-&dgr;, where A is Ba, Pb, Na, K, Y, an element of the lanthanide group or a combination thereof, B is Mg, Al, Ga, In, Sn, an element of the 3d or 4d period or a combination thereof, x is from 0.2 to 0.8, y is from 0 to 0.4, z is from 0 to 0.6, and &dgr; is a number, dependent on x, y and z, that renders the composition charge neutral.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: May 4, 2004
    Assignee: BASF Aktiengesellschaft
    Inventors: Stefan Bitterlich, Hartwig Voss, Hartmut Hibst, Andreas Tenten, Ingolf Voigt, Ute Pippardt
  • Patent number: 6703379
    Abstract: The present invention provides an AP-1 activation inhibitor, NF-kappa B activation inhibitor, inflammatory cytokine production inhibitor, matrix metalloprotease production inhibitor, inflammatory cell adhesion molecule expression inhibitor, anti-inflammatory agent, antirheumatic agent, immunosuppressant, cancer metastasis inhibitor, remedy for arteriosclerosis and antiviral agent which contain the benzene derivative of the following general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Grant
    Filed: March 12, 2001
    Date of Patent: March 9, 2004
    Assignee: Ajinomoto Co., Inc.
    Inventors: Yukio Iino, Kohichi Fujita, Takashi Tsuji, Ariko Kodaira, Kenji Takehana, Tsuyoshi Kobayashi, Takashi Yamamoto
  • Patent number: 6660736
    Abstract: This invention relates to phthalimido derivatives of the formula wherein X is —N═ or —CH═, and R1 to R4 and m are as defined in the specification, as well as their pharmaceutically acceptable salts. The invention further relates to pharmaceutical compositions containing these compounds, a method of treating a disease by administering a therapeutically effective amount of at least one of these compounds, and a process for their preparation for the treatment or prevention of diseases in which MAO-B inhibitors might be beneficial.
    Type: Grant
    Filed: March 13, 2003
    Date of Patent: December 9, 2003
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Andrea Cesura, Rosa Maria Rodriguez Sarmiento, Andrew William Thomas, Rene Wyler
  • Patent number: 6657068
    Abstract: A method for the manufacture of halophthalic acid by liquid phase oxidation of halo-ortho-xylene is disclosed. The halophthalic acid may be dehydrated to form halophthalic anhydride which is useful in the synthesis of polyetherimide.
    Type: Grant
    Filed: March 22, 2002
    Date of Patent: December 2, 2003
    Assignee: General Electric Company
    Inventors: Robert Edgar Colborn, David Bruce Hall, Peter Koch, Gerald Oeckel
  • Patent number: 6657067
    Abstract: A method for the manufacture of chlorophthalic acid by liquid phase oxidation of chloro-ortho-xylene is disclosed. The chlorophthalic acid may be dehydrated to form chlorophthalic anhydride which is useful in the synthesis of polyetherimide.
    Type: Grant
    Filed: March 22, 2002
    Date of Patent: December 2, 2003
    Assignee: General Electric Company
    Inventors: Robert Edgar Colborn, David Bruce Hall, Peter Koch, Gerald Oeckel
  • Patent number: 6649773
    Abstract: A method for the manufacture of halophthalic acid by liquid phase oxidation of halo-ortho-xylene is disclosed. The halophthalic acid may be dehydrated to form halophthalic anhydride which is useful in the synthesis of polyetherimide.
    Type: Grant
    Filed: March 22, 2002
    Date of Patent: November 18, 2003
    Assignee: General Electric Company
    Inventors: Robert Edgar Colborn, David Bruce Hall, Peter Koch, Gerald Oeckel
  • Patent number: 6512124
    Abstract: A self-polymerizable AB2 monomer of the formula The resulting AB2 monomer can be polymerized to afford high molecular, low viscosity hyperbranched ether-ketone-imide polymer having repeating units with hydroxyl endgroups.
    Type: Grant
    Filed: February 27, 2002
    Date of Patent: January 28, 2003
    Assignee: The United States of America as represented by the Secretary of the Air Force
    Inventors: Jong-Beom Baek, Loon-Seng Tan
  • Publication number: 20020133007
    Abstract: Novel herbicidal and defoliant substituted aniline derived compounds represented by general structure (I) 1
    Type: Application
    Filed: August 16, 2001
    Publication date: September 19, 2002
    Applicant: ISK AMERICAS INCORPORATED
    Inventors: Sandeep Gupta, Shao-Yong Wu, Masamitsu Tsukamoto, David A. Pulman, Bai-Ping Ying
  • Patent number: 6433184
    Abstract: The present invention relates to polyamide-imides having head-to-tail backbone and more particularly, to polyamide-imimdes having head-to-tail ragularity to provide excellent heat and chemical resistance, physical and mechanical properties, processability, and gas permeability and selectivity.
    Type: Grant
    Filed: June 28, 2000
    Date of Patent: August 13, 2002
    Assignee: Korea Research Institute of Chemical Technology
    Inventors: Kil-Yeong Choi, Jae Heung Lee, Young-Taik Hong, Moon Young Jin, Kyoung-Su Choi, Ho-Jin Park
  • Patent number: 6429221
    Abstract: Novel imides are inhibitors of tumor necrosis factor &agr; and can be used to combat cachexia, endotoxic shock, and retrovirus replication. A typical embodiment is 2-Phthalimido-3-(3′,4′-dimethoxyphenyl)propane.
    Type: Grant
    Filed: December 30, 1994
    Date of Patent: August 6, 2002
    Assignee: Celgene Corporation
    Inventors: George W. Muller, Mary Shire, David I. Stirling
  • Patent number: 6365753
    Abstract: A phthalimide represented by general formula (I): wherein L represents L-1 or L-2: (wherein R1 and R2 each independently represent a hydrogen atom, an alkyl group, etc.); A represents an oxygen atom, a sulfur atom or —NR5— (wherein R5 is a hydrogen atom, an alkyl group, an alkenyl group, etc.); R represents a hydrogen atom, an alkyl group, an alkenyl group, a cycloalkyl group, a phenyl group, etc.; X represents a halogen atom; Y represents a hydrogen atom or a halogen atom; and Z represents a hydrogen atom, an alkyl group, a haloalkyl group or a halogen atom. The compound exhibits excellent herbicidal effects with high selectivity.
    Type: Grant
    Filed: March 8, 2001
    Date of Patent: April 2, 2002
    Assignee: Mitsubishi Chemical Corporation
    Inventors: Bunji Natsume, Mitsuru Hikido, Shinji Kawaguchi